(Q40572162)

21 September 2017

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. (English)

1 reference

21 September 2017

2

1 reference

21 September 2017

7

Susanne Krüger Kjaer

0 references

Philip E. Castle

5

object named as

Philip E Castle

1 reference

21 September 2017

Diana V Pastrana

1

1 reference

21 September 2017

Yuk-Ying S Pang

3

1 reference

21 September 2017

Cynthia D Thompson

4

1 reference

21 September 2017

Peter C FitzGerald

6

1 reference

21 September 2017

Susanne Krüger Kjaer

7

1 reference

21 September 2017

Douglas R Lowy

8

1 reference

21 September 2017

John T Schiller

9

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

21 September 2017

1 reference

21 September 2017

321

1 reference

21 September 2017

2

1 reference

21 September 2017

205-216

1 reference

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Efficient intracellular assembly of papillomaviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Neutralization of CRPV infectivity by monoclonal antibodies that identify conformational epitopes on intact virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Papillomaviruses infect cells via a clathrin-dependent pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

The serological response to papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

A quantitative in vitro focus assay for bovine papilloma virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Clinical, histopathologic, and molecular aspects of cutaneous human papillomavirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Papillomavirus vaccines in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Immunological analyses of human papillomavirus capsids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Clinical presentation and natural course of anogenital warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Neutralizing antibodies against oncogenic human papillomavirus as a possible determinant of the fate of low-grade cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Human papillomavirus—the most significant risk determinant of cervical intraepithelial neoplasia

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

7 January 2021

Immunity to oncogenic human papillomaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Detection of serologic neutralizing antibodies against HPV-11 in patients with condyloma acuminata and cervical dysplasia using an in vitro assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Assembly of human papillomavirus type 16 pseudovirions in Saccharomyces cerevisiae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Papillomavirus-like particle based vaccines: cervical cancer and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Infectious human papillomavirus type 18 pseudovirions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

In vitro gene transfer using human papillomavirus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Evaluation of Seroreactivity to Human Papillomavirus Type 16 Virus-like Particles in an Incident Case-Control Study of Cervical Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Nucleotides 1506-1625 of bovine papillomavirus type 1 genome can enhance DNA packaging by L1/L2 capsids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

7 January 2021

Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

7 January 2021

Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.027

7 January 2021

10.1016/J.VIROL.2003.12.027

Identifiers

DOI

1 reference

21 September 2017

1 reference